StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $0.46 on Friday. Evoke Pharma has a 12 month low of $0.42 and a 12 month high of $2.40. The company’s 50 day moving average is $0.59 and its 200-day moving average is $0.90.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The firm had revenue of $1.68 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 4/22 – 4/26
- What Are Dividend Achievers? An Introduction
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
